Pfizer (PFE) Stock News

Pfizer expects fiscal year adjusted EPS in the range of $2.95 to $3.05.

Pfizer previously guided 2026 revenue at $60.5B-$62.5B.

Pfizer reported Q3 2026 operational revenue growth driven by Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena, offset by declines in Paxlovid, Comirnaty, and Prevnar. R&D expenses rose 18% operationally. Recent developments include FDA approval for updated COVID vaccine and Phase 3 results for Elrexfio.

Pfizer reported third-quarter adjusted earnings per share of 87 cents. The figure comes from a preliminary headline; no revenue, year-ago comparison, or guidance was provided.

Pfizer posted $16.58 billion in revenue for the third quarter.

Pfizer reported Q3 2026 revenues of $16.6B, relatively flat YoY, but ex-COVID products grew 7% operationally. The company raised full-year revenue and EPS guidance. Cecile Guegan was appointed CFO effective Nov 1.

Pfizer named Cecile Guegan as its new chief financial officer. No effective date or additional details were disclosed.

JP Morgan increased its price target for Pfizer from $28.00 to $30.00 per share.

Pfizer announced FDA approval of TUKYSA (tucatinib) plus trastuzumab and pertuzumab for front-line maintenance in HER2+ metastatic breast cancer. The HER2CLIMB-05 trial showed a 35.9% reduction in progression risk and 8.6-month median PFS improvement. TUKYSA carries a boxed warning for hepatotoxicity. The label expansion moves TUKYSA to an earlier treatment line.

Pfizer's board declared a $0.43 per share Q4 dividend, payable Dec 7 to holders of record Nov 6. It is the 352nd consecutive quarterly dividend.

Pfizer will present 45 abstracts at ESMO 2026, including Phase 2 data for atirmociclib in breast cancer, Phase 3 results for sigvotatug vedotin in NSCLC, and updated Phase 2 data for tivunatamig in NSCLC. New analyses for PADCEV and TALZENNA will also be featured. The TALZENNA sNDA is under FDA Priority Review.

Health Canada authorized the updated Omicron XFG Covid-19 vaccine from Pfizer and BioNTech. Distribution will start in the coming days and weeks.

A claim on social media reports that Pfizer (PFE) stock hit a new 52-week high today. The report is unverified and lacks additional context or price details.